Abstract More than 400 compounds isolated from soil microorganisms, and catalogued in the antibiotic library of the Kitasato Institute for Life Sciences, were screened against African trypanosomes. Ten compounds were found to have selective and potent antitrypanosomal activity in vitro: aureothin, cellocidin, destomycin A, echinomycin, hedamycin, irumamycin, LL-Z 1272b , Omethylnanaomycin A, venturicidin A and virustomycin A. Results of the in vitro assays using the GUTat 3.1 strain of Trypanosomal brucei brucei and the STIB900 strain of T. b. rhodesiense are presented. Cytotoxicity was determined using a human MRC-5 cell line. This is the first report of antitrypanosomal activities of the 10 microbial metabolites listed above.
Introduction
African trypanosomes, protozoan parasites of the genus Trypanosoma, transmitted through the bite of bloodfeeding tsetse flies (Glossina spp.), cause disease in cattle and in people. Human African trypanosomiasis (HAT), also known as sleeping sickness, is caused by infection with Trypanosoma brucei rhodesiense or T. b. gambiense and is a major threat to communities throughout sub-Saharan Africa. A third subspecies, T. b. brucei is responsible for the cattle disease, N'gana, but does not infect humans. Accurate statistics for HAT are difficult to estimate the World Health Organization (WHO) estimated that, in 2000, some 300,000 individuals were affected by the disease, a figure far in excess of the 27,000 cases reportedly diagnosed and treated that year. With increased surveillance activities in the last 7 years, recent estimates indicate that there are 70,000 cases, causing 25,000 deaths annually [1, 2] .
Currently, only four drugs are registered for the treatment of HAT: pentamidine, suramin, melarsoprol and eflornithine ( Fig. 1 ). Pentamidine and suramin are used in the first or early stage of T. b.gambiense and T. b. rhodesiense infections. Melarsoprol is used in the advanced stage of both forms of the disease, while eflornithine is only used in the advanced stage of T. b. gambiense infections and is not effective against T. b. rhodesiense. Today, increasing numbers of patients, 20ϳ25% in certain foci, are no longer responding to melarsoprol treatment, probably due to evolving drug resistance. Although expensive, eflornithine is an effective alternative drug for the treatment of T. b. gambiense patients who do not respond to melarsoprol [3] .
All four drugs used to treat HAT are unsatisfactory, since they cannot be given orally and all are hampered by severe toxicity and increasing resistance of the parasites.
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Melarsoprol for example, the only drug for 2 nd -stage infections caused by T. b. rhodesiense, causes around 5.0% fatalities due to severe adverse effects [4] . Consequently, there is an urgent need for new antitrypanosomal drugs which have novel structures and mechanisms of action and which are both safe and effective.
In the course of our screening program to discover new antitrypanosomal antibiotics, by screening metabolites from soil microorganisms, we have discovered 10 compounds that display potent antitrypanosomal activity in vitro. We report the results of sensitivity tests on the GUTat 3.1 strain of T. b. brucei and the STIB900 strain of T. b. rhodesiense using the four commonly used antitrypanosomal drugs as well as detailing the novel antitrypanosomal activity and cytotoxicity of the ten antibiotics in vitro.
Materials and Methods
Parasites and History
Trypanosoma brucei brucei strain GUTat 3.1 (Glasgow University, Trypanozoon antigenic type 3.1) was donated Dr. Y. Yabu (Nagoya City University, Japan). It is a cloned derivative of a stock EVE (Edinburgh Veterinary Expedition) 10 that was originally isolated in 1996 from a naturally infected bovine in Uganda. containing 10% heat-inactivated FBS at 37°C, under 5.0% CO 2 -95% air, according to the method of Yabu et al. [5] . T. b. rhodesiense STIB900 strain was cultured in MEM with Earle's salts supplemented with 25 mM HEPES, 1.0 g/liter additional glucose, 2.2 g/liter NaHCO 3 , 10 ml/liter MEM non-essential amino acids (100ϫ), 0.2 mM 2-mercaptoethanol, 1.0 mM sodium pyruvate, 0.1 mM hypoxanthine 50 Unit/ml of penicillin and 50 mg/ml of streptomycin containing 15% heat-inactivated HS at 37°C, under 5.0% CO 2 -95% air, according to the method of Baltz et al. [6] . In vitro antitrypanosomal activity of test compounds was determined by a dose response curve using Alamar Blue according to the method of Räz et al. and Tasdemir et al. [7, 8] with some modification. Ninety five m l of the trypanosomes suspension (2.0ϳ2.5ϫ10 4 trypanosomes/ml for GUTat 3.1 strain or 2.0ϳ3.0ϫ10 4 trypanosomes/ml for STIB 900 strain) of bloodstream forms was seeded in a 96-well microplate, and 5.0 m l of a test compound solution (dissolved in 5.0% dimethylsulfoxide) was added. After the incubation for 72 hours at 37°C under 5.0% CO 2 -95% air, 10 m l of the fluorescent dye Alamar Blue was added to each well. After a further incubation for 3ϳ6 hours at 37°C under 5.0% CO 2 -95% air, the plate was read at 528/20 nm excitation wavelength and 590/35 nm emission wavelength by a FLx800 fluorescent plate reader (Bio-Tek Instrument, Inc. Vermont, USA). Data were transferred into a graphic program (Excel) and the IC 50 values were determined by using the fluorescent plate reader software (KC-4, BioTek).
Stock cultures were kept in 24-well tissue culture plates at 37°C under 5.0% CO 2 -95% air.
Cytotoxicity Tests on MRC-5 Cells
Cytotoxicity was assayed against a human diploid embryonic cell line MRC-5 as described previously [9] .
Results
Antitrypanosomal Activity and Cytotoxicity of Currently Used Drugs
The drug sensitivity of the GUTat 3.1 strain is not known. Conversely, the STIB900 strain is known to be susceptible to all existing antitrypanosomal drugs [10] . We therefore first established the in vitro drug sensitivity of the GUTat 3.1 and the STIB900 strains against the four common trypanocidal drugs. Suramin, pentamidine, melarsoprol and eflornithine were tested against the two T. brucei strains and MRC-5 cells and IC 50 values were determined (Table  1) . Melarsoprol showed the highest antitrypanosomal activity against both parasite strains. The GUTat 3.1 strain was 85-fold more sensitive to the drug than STIB900. The sensitivity to pentamidine was the same for both strains. For suramin, STIB900 was 30-fold more sensitive than GUTat 3.1 while for eflornithine the sensitivity was only double. The cytotoxicity of the existing drug was also determined using MRC-5 cells. Melarsoprol and pentamidine showed IC 50 values in the low m g/ml range whereas for suramin and eflornithine, the IC 50 values were Ͼ100 mg/ml.
To compare the antitrypanosomal activities and cytotoxicities, we calculated the selectivity index (SI: [IC 50 for MRC-5 cells]/[IC 50 for trypanosome strain]) ( Table 1) . The SIs were in a range Ͼ44 to 127,273 for GUTat 3.1 and in a range Ͼ96 to 3,807 for STIB900. Melarsoprol and pentamidine present SI values Ͼ1,000, peaking at Ͼ100,000 for melarsoprol and the GUTat 3.1 strain. For eflornithine it is difficult to determine a reasonable SI value because very high drug concentrations are tolerated by mammalian cells. 
In Vitro Antitrypanosomal Activity and Cytotoxicity of 10 Antibiotics
The in vitro antitrypanosomal activity of the 10 microbial metabolites was determined using GUTat 3.1 (T. b. brucei) and STIB900 (T. b. rhodesiense). The IC 50 values are presented in Table 2 . Virustomycin A and aureothin showed the highest antitrypanosomal activity, with IC 50 values around 1.0 ng/ml which is comparable to pentamidine (Tables 1 and 2) . Echinomycin, hedamycin, irumamycin and LL-Z 1272b were 10-fold less active than virustomycin A and aureothin, with IC 50 values of 14ϳ59 ng/ml for both trypanosome strains. Cellocidin, destomycin A, Omethylnanaomycin A and venturicidin A were the least active compounds against GUTat 3.1 but their IC 50 values can still be considered as active. Interestingly, cellocidin and O-methylnanaomycin A resulted in much lower IC 50 values for STIB900 as compared to the GUTat 3.1 strain. The cytotoxicity of the 10 compounds were evaluated against a human diploid embryonic cell line (MRC-5). The IC 50 values are listed in Table 2 . Virustomycin A was the only compound with a pronounced cytotoxicity, having an IC 50 value of 80 ng/ml. Cellocidin, echinomycin and Omethylnanaomycin A were revealed to be slightly cytotoxic, demonstrating IC 50 values of 5ϳ6 mg/ml, while the remaining six compounds had IC 50 values of Ͼ12.5 mg/ml and do not seem to be cytotoxic.
Among the tested compounds, aureothin showed the highest SI with values of Ͼ17,857 for GUTat 3.1 and Ͼ22,727 for STIB900. It exhibited a significantly better SI value for T. b. rhodesiense than any other compound. Echinomycin, hedamycin, irumamycin, LL-Z 1272b , venturicidin A and virustomycin A showed SIs Ͼ100 for GUTat 3.1. The SI values for cellocidin and destomycin A were in a lower range of 40ϳ180, based on the lower antitrypanosomal activity of these compounds.
Discussion
Aureothin is a g-pyrone antibiotic, and is reported to have antitumor, antifungal and pesticide activity [11ϳ13], and we previously reported that it showed potent nematocidal activity against the pine wood nematode [14] . The mode of action of aureothin has been reported as a non-specific inhibition of NADH: ubiquinone oxidoreductase (complex I) on bovine heart, fungal and bacterial cells [15] .
Cellocidin is an amide antibiotic, and is reported to have antitumor and antibacterial activity [16, 17] . The mode of action of cellocidin is via inhibition of the a-ketoglutaratesuccinate system in the Krebs' cycle in Xanthomonas oryzae [18] and inhibition of nucleic acid synthesis in tumor cells [19] .
Destomycin A is an aminoglycoside antibiotic and is reported to have antibacterial and anthelmintic activity [20ϳ22] . The mode of action of destomycin A is the inhibition of polypeptide synthesis in cells of Escherichia coli and stimulation of adenylate cyclase in several animal tissues [23, 24] .
Echinomycin is a cyclic depsipeptide antibiotic containing two quinoxaline moieties and is reported to have antibacterial and antitumor activity [25, 26] . The mode of action of echinomycin is reported to be intercalation with 375 DNA [25, 26] . Hedamycin is an anthraquinone antibiotic exhibiting antitumor, antibacterial and anti-Tetrahymena pyriformis (anti-protozoal) activity [27] . Recently, we reported that it also possesses selective and potent antimalarial activity [28] . The mode of action of anthraquinone antibiotics is inhibition of nucleic acid synthesis [27] .
LL-Z 1272b is a terpenoid antibiotic and is reported to have anti-T. pyriformis (anti-protozoal) and antitumor activity [29, 30] , and we reported that it showed inhibition of testosterone 5a -reductase from rat prostate [31] . A related antibiotic, ascofuranone, is reported to have in vitro and in vivo anti-trypanosomal activities [32, 33] . The mode of action of ascofuranone is inhibition of the mitochondrial electron-transport system in trypanosomes [32] .
O-Methylnanaomycin A is a semi-synthetic analogue of nanaomycin A, a naphtoquinone antibiotic, and Omethylnanaomycin A is reported to exhibit antifungal activity [34] . The mode of action of nanaomycin A is via inhibition of the respiratory chain-linked flavin dehydrogenase in bacterial cells [35] .
Irumamycin and venturicidin A are similar to the 20-membered ring macrolide antibiotics and both antibiotics are reported to have antifungal activity [36, 37] . For venturicidin A, antimalarial activity has also identified [38] . The mode of action of venturicidin A is inhibition of phosphoryl transfer reactions (in rat liver mitochondria) and inhibition of mitochondrial adenosine triphosphatase of T. pyriformis [39, 40] .
Virustomycin A is an 18-membered ring macrolide antibiotic, reportedly having antiviral and anti-Trichomonas foetus (anti-protozoal) activities [41, 42] . The mode of action of virustomycin A is through interference with the formation of the phosphate donor(s) in the ATP-forming system (in T. foetus) [42] .
Recently, Berriman et al., proposed several molecular targets in T. brucei determined from the available sequence of the T. brucei genome. One of them is mitochondorial electron transport and oxidative phosphorylation, including ATP synthase [43] . Some of the antitrypanosomal antibiotics we describe in this article (aureothin, cellocidin, the ascofuranone related LL-Z 1272b , Omethylnanaomycin A, irumamycin, venturicidin A and virusomycin A) may actually inhibit T. brucei by inhibition of mitochondrial functions.
The mode of action of aminoglycoside antibiotics, such as destomycin A, is via inhibition of polypeptide synthesis, that of cyclic depsipeptide antibiotics (such as echinomycin) via intercalation with DNA, and anthraquinone antibiotics (such as hedamycin) through inhibition of nucleic acid synthesis are all well documented [23, 25ϳ27] . Destomycin A, echinomycin and hedamycin may also inhibit T. brucei in the same manner and detailed studies of the mode of action need to be undertaken to provide further evidence.
Further studies, including in vivo tests in animal models of trypanosomal infection and characterization of other biological activities of aureothin, cellocidin, destomycin A, echinomycin, hedamycin, irumamycin, LL-Z 1272b , Omethylnanaomycin A, venturicidin A and virustomycin A are in progress.
